Scarica l'app Stockscreener
12.91
4.48%
-0.603
Precedente Chiudi:
$13.52
Aprire:
$13.91
Volume 24 ore:
384.32K
Relative Volume:
0.46
Capitalizzazione di mercato:
$1.36B
Reddito:
-
Utile/perdita netta:
$-115.88M
Rapporto P/E:
-8.3476
EPS:
-1.5468
Flusso di cassa netto:
$-104.72M
1 W Prestazione:
-9.47%
1M Prestazione:
+2.38%
6M Prestazione:
-51.04%
1 anno Prestazione:
-18.70%
Intervallo 1D:
$12.54
$13.91
Intervallo di 1 settimana:
$12.54
$14.50
Portata 52W:
$10.60
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Nome
Edgewise Therapeutics Inc
Settore
Industria
Telefono
720-262-7002
Indirizzo
1715 38TH ST, BOULDER
Confronta EWTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
12.91 | 1.45B | 0 | -115.88M | -104.72M | -1.5468 |
|
VRTX
Vertex Pharmaceuticals Inc
|
377.71 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.66 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.63 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
668.20 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
296.01 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Iniziato | Raymond James | Strong Buy |
| 2025-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2025-04-30 | Iniziato | Guggenheim | Buy |
| 2025-04-02 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-01-22 | Iniziato | Stifel | Hold |
| 2024-11-22 | Iniziato | Evercore ISI | Outperform |
| 2024-03-07 | Iniziato | Piper Sandler | Overweight |
| 2023-05-01 | Iniziato | Truist | Buy |
| 2022-08-25 | Downgrade | Goldman | Neutral → Sell |
| 2022-04-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-01-28 | Iniziato | Goldman | Neutral |
Mostra tutto
Edgewise Therapeutics Inc Borsa (EWTX) Ultime notizie
Edgewise Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Raymond James reiterates Strong Buy on Edgewise Therapeutics stock with $46 price target - Investing.com Canada
Edgewise Therapeutics' Accelerating Clinical Pipeline: A Catalyst for Valuation Re-rating in 2025? - AInvest
Edgewise Therapeutics shares surge as Q2 loss narrows, beats estimates By Investing.com - Investing.com South Africa
Edgewise Therapeutics: Pioneering Muscle Disease Innovation with Strong Q2 Results and Promising Late-Stage Pipeline - AInvest
Edgewise Therapeutics, Inc. SEC 10-Q Report - TradingView
Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - PR Newswire
Applying Wyckoff theory to Edgewise Therapeutics Inc. stockLow Risk Trade Timing with Analysis Metrics - Newser
Edgewise Therapeutics Inc. stock trendline breakdownHigh Yield Signals with Entry Timing - Newser
Edgewise Therapeutics (EWTX) to Release Earnings on Thursday - MarketBeat
TD Asset Management Inc Buys New Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics Grants $1.2M Stock Options Package: New Hires Get Equity at $14.26 Per Share - Stock Titan
How Edgewise Therapeutics Inc. stock performs during market volatilityIntraday Strategy with Real Time Monitoring - Newser
Is Edgewise Therapeutics Inc. stock poised for growthSector Rotation Outlook With Historical Summary - Newser
Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 3.9%Here's Why - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Edgewise Therapeutics, Inc. (EWTX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Edgewise EWTX 2025Q2 Earnings Preview Upside Potential Amid Clinical Trial Progress - AInvest
Pomerantz LLP investigates Edgewise Therapeutics over potential securities fraud claims. - AInvest
Quantitative breakdown of Edgewise Therapeutics Inc. recent moveMomentum Trading Guide with Safety Limits - Newser
Visualizing Edgewise Therapeutics Inc. stock with heatmapsDaily Breakout List with Smart Filters - Newser
Can Edgewise Therapeutics Inc. Bounce Back From Weekly LowReversal Alert Based on RSI Indicator Confirmed - metal.it
How Interest Rate Changes Impact Edgewise Therapeutics Inc. Stock PerformanceBuy Strategy with Smart Exit Timing - Newser
What is the risk reward ratio of investing in Edgewise Therapeutics Inc. stockGet timely alerts on top-performing stocks - Jammu Links News
What analysts say about Edgewise Therapeutics Inc. stockInvest confidently with real-time market updates - Jammu Links News
Is Edgewise Therapeutics Inc. stock overvalued or undervaluedFree Consultation - Jammu Links News
Edgewise Therapeutics (NASDAQ:EWTX) Trading 8.3% HigherHere's Why - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Edgewise Therapeutics, Inc. (EWTX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
What drives Edgewise Therapeutics Inc. stock priceBuild wealth steadily with expert advice - Jammu Links News
Does Edgewise Therapeutics Inc. stock perform well during market downturnsUnlock your portfolio’s full growth potential - Jammu Links News
What catalysts could drive Edgewise Therapeutics Inc. stock higher in 2025Unlock exclusive trading tools and resources - Jammu Links News
Does Edgewise Therapeutics Inc. qualify in momentum factor screeningHigh Probability Trade Outcome Prediction - Newser
What makes Edgewise Therapeutics Inc. stock price move sharplyFree Daily Stock Market Swing Alerts - newser.com
What is the dividend policy of Edgewise Therapeutics Inc. stockAchieve consistent high returns with low risk - Jammu Links News
37,591 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Bought by Skandinaviska Enskilda Banken AB publ - MarketBeat
How many analysts rate Edgewise Therapeutics Inc. as a “Buy”Stay ahead with daily expert stock picks - Jammu Links News
Is it the right time to buy Edgewise Therapeutics Inc. stockGain insights from top financial experts - Jammu Links News
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Edgewise Therapeutics, Inc. (EWTX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Is Edgewise Therapeutics Inc. Stock a Good Fit for Conservative InvestorsTrade Plan With Low Risk High Return - Newser
Bronstein, Gewirtz & Grossman, LLC Is Investigating Edgewise Therapeutics, Inc. (EWTX) And Encourages Shareholders to Connect - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc.EWTX - FinancialContent
Raymond James Initiates Strong Buy on Edgewise Therapeutics (EWTX) with $46 PT, Cites EDG-7500 Potential for HCM - Insider Monkey
Edgewise Therapeutics Initiates Coverage with Strong Buy Rating - AInvest
Bronstein, Gewirtz & Grossman, LLC Encourages Edgewise Therapeutics, Inc. (EWTX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc.EWTX - MarketScreener
Edgewise Therapeutics (NASDAQ:EWTX) Now Covered by Raymond James Financial - MarketBeat
Heatmap analysis for Edgewise Therapeutics Inc. and competitorsSmart Stock Forecast Using AI Algorithms - Newser
Published on: 2025-07-31 00:37:16 - Newser
How sentiment analysis helps forecast Edgewise Therapeutics Inc.Free Weekly Top Gainers Forecast Watchlist - Newser
Edgewise Therapeutics shares fall 1.62% after-hours despite Raymond James initiating a Strong Buy rating. - AInvest
Edgewise Therapeutics Inc Azioni (EWTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Edgewise Therapeutics Inc Azioni (EWTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Russell Alan J | Chief Scientific Officer |
May 02 '25 |
Sale |
16.45 |
1,551 |
25,520 |
18,521 |
| MOORE JOHN R | General Counsel |
May 01 '25 |
Option Exercise |
0.00 |
5,209 |
0 |
8,461 |
| MOORE JOHN R | General Counsel |
May 02 '25 |
Sale |
16.45 |
1,930 |
31,757 |
6,531 |
| KOCH KEVIN | President and CEO |
May 01 '25 |
Option Exercise |
0.00 |
10,417 |
0 |
24,895 |
| KOCH KEVIN | President and CEO |
May 02 '25 |
Sale |
16.45 |
4,276 |
70,358 |
20,619 |
| Donovan Joanne M. | CMO |
May 01 '25 |
Option Exercise |
0.00 |
10,417 |
0 |
26,775 |
| Donovan Joanne M. | CMO |
May 02 '25 |
Sale |
16.45 |
5,187 |
85,348 |
21,588 |
| Derakhshan Behrad | Chief Business Officer |
May 01 '25 |
Option Exercise |
0.00 |
5,209 |
0 |
22,046 |
| Derakhshan Behrad | Chief Business Officer |
May 02 '25 |
Sale |
16.45 |
1,691 |
27,824 |
20,355 |
| Carruthers R Michael | Chief Financial Officer |
May 01 '25 |
Option Exercise |
0.00 |
5,209 |
0 |
82,328 |
0.14%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):